Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710593 · ClinicalTrials.gov registry record · Phase 2
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
A Phase 2 study of HIV Infection, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT00710593 is a Phase 2 study of HIV Infection that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 99 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (59% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT00710593, a Phase 2 study of HIV Infection, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
Conditions Studied
Interventions
- BIOLOGICAL HPV vaccine for strains -6, -11, -16, and -18
Study Locations (14)
Florida
- Childrens Diagnostic & Treatment Center - Fort Lauderdale
- University of Miami School of Medicine - Miami
- USF College of Medicine - Tampa
Illinois
- Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital - Chicago
- Childrens Memorial Hospital - Chicago
New York
- Mount Sinai Medical Center - New York
- Montefiore Medical Center - The Bronx
California
- Childrens Hospital of Los Angeles - Los Angeles
District of Columbia
- Childrens National Medical Center - Washington D.C.
Louisiana
- Tulane University Health Sciences Center - New Orleans
Maryland
- University of Maryland - Baltimore
Pennsylvania
- Childrens Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710593
The ClinicalTrials.gov registry entry for NCT00710593 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (59% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV vaccine for strains -6, -11, -16, and -18 is the first listed.
NCT00710593 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00710593 about?
NCT00710593 is a clinical study titled "Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women". The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
What is the current status of trial NCT00710593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2008-02. Estimated completion is 2011-02.
What conditions does trial NCT00710593 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00710593?
The interventions under investigation include: HPV vaccine for strains -6, -11, -16, and -18 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00710593?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00710593 being conducted?
This trial has 14 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
-
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.